Prognostic Factors and Risk Models in Myelodysplastic Syndromes
Authors:
- Rami S. KomrokjiRKRami S. Komrokji
- Eric PadronEPEric Padron
- Jeffrey E. LancetJLJeffrey E. Lancet
- Alan F. ListALAlan F. List
- 1 September 2013
- journal article
- review article
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 13, S295-S299
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- The Spliceosome as an Indicted Conspirator in Myeloid MalignanciesCancer Cell, 2011
- Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndromeCancer, 2011
- Clinical Effect of Point Mutations in Myelodysplastic SyndromesNew England Journal of Medicine, 2011
- Association of Comorbidities With Overall Survival in Myelodysplastic Syndrome: Development of a Prognostic ModelJournal of Clinical Oncology, 2011
- Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndromeHaematologica, 2010
- Obesity, Lifestyle Factors, and Risk of Myelodysplastic Syndromes in a Large US CohortAmerican Journal of Epidemiology, 2009
- Clinical Relevance of Bone Marrow Fibrosis and CD34-Positive Cell Clusters in Primary Myelodysplastic SyndromesJournal of Clinical Oncology, 2009
- Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring SystemCancer, 2008
- Identification of RPS14 as a 5q- syndrome gene by RNA interference screenNature, 2008
- A prognostic score for patients with lower risk myelodysplastic syndromeLeukemia, 2007